{
  "as_of": "2026-11-03",
  "track": "degraders",
  "source_url": "https://drugnews.com.tw/en/asia-degraders-leaders.html",
  "headers": [
    "rank",
    "asset",
    "inn",
    "originator",
    "country",
    "target",
    "mechanism",
    "highest_stage",
    "indications",
    "trial_ids",
    "overseas_rights_holder",
    "deal_date",
    "upfront",
    "total_value",
    "latest_event",
    "latest_event_date",
    "source_urls",
    "source_date"
  ],
  "rows": [
    [
      "1",
      "GT20029",
      "—",
      "Kintor Pharmaceutical Limited (Suzhou Kintor)",
      "China",
      "Androgen receptor (AR)",
      "Topical AR-targeting PROTAC degrader",
      "Phase 2 — China (2023-04)",
      "Androgenetic alopecia; acne vulgaris",
      "NCT06692465",
      "None reported",
      "—",
      "—",
      "—",
      "China acne Phase 2 met its primary endpoint, company announcement",
      "2025-08-12",
      "https://www.prnewswire.com/news-releases/gt20029-china-phase-ii-trial-for-aga-reached-primary-endpoint-302122889.html | https://en.kintor.com.cn/news/p-6-6.html | https://www.kintor.com.cn/msg.html | https://clinicaltrials.gov/study/NCT06692465",
      "2025-08-12"
    ],
    [
      "2",
      "HP518",
      "—",
      "Hinova Pharmaceuticals Inc.",
      "China",
      "Androgen receptor (AR)",
      "Oral AR-targeting PROTAC degrader",
      "Phase 2 — China (2024-12)",
      "Metastatic castration-resistant prostate cancer",
      "NCT06155084",
      "None reported",
      "—",
      "—",
      "—",
      "Hinova interim disclosure describes China Phase 2 development and combination IND progress",
      "2026-08-27",
      "https://www.hinovapharma.com/en/about.html | https://static.cninfo.com.cn/finalpage/2026-08-27/1225514360.PDF | https://clinicaltrials.gov/study/NCT06155084",
      "2026-08-27"
    ],
    [
      "3",
      "HRS-1358",
      "—",
      "Jiangsu Hengrui Pharmaceuticals Co., Ltd.",
      "China",
      "Estrogen receptor (ER)",
      "Oral ER-targeting PROTAC degrader",
      "Phase 2 — China (confirmed 2025-05; combination)",
      "Advanced breast cancer, combination therapy",
      "NCT06555068 | NCT06679036",
      "None reported",
      "—",
      "—",
      "—",
      "Combination-study registry updated; recruiting",
      "2026-10-22",
      "https://www.hengrui.com/images/investor/hk/2.%20Prospectus/2.%20Offer%20for%20Subscription%20%28EN%29.pdf | https://static.cninfo.com.cn/finalpage/2026-03-26/1225032585.PDF | https://static.cninfo.com.cn/finalpage/2026-08-20/1225483600.PDF | https://clinicaltrials.gov/study/NCT06555068 | https://clinicaltrials.gov/study/NCT06679036",
      "2026-10-22"
    ],
    [
      "4",
      "ICP-490",
      "—",
      "InnoCare Pharma / Beijing InnoCare Pharma Tech Co., Ltd.",
      "China",
      "IKZF1 (Ikaros); IKZF3 (Aiolos)",
      "CRBN-recruiting molecular glue degrader",
      "Phase 1/2 — China (2023-03; registry status unknown)",
      "Relapsed/refractory multiple myeloma; non-Hodgkin lymphoma",
      "NCT05719701 | NCT06845241",
      "None reported",
      "—",
      "—",
      "—",
      "NHL Phase 1/2 registered; not yet recruiting",
      "2025-02-25",
      "https://www.innocarepharma.com/en/news/activity/en020220706 | https://www.innocarepharma.com/en/contact | https://clinicaltrials.gov/study/NCT05719701 | https://clinicaltrials.gov/study/NCT06845241",
      "2025-02-25"
    ],
    [
      "5",
      "HSK29116",
      "—",
      "Haisco Pharmaceutical Group Co., Ltd.",
      "China",
      "Bruton tyrosine kinase (BTK)",
      "BTK-targeting PROTAC degrader",
      "Phase 1 — China / Australia (2021-08; registry status unknown)",
      "Relapsed/refractory B-cell malignancies",
      "NCT04861779",
      "None reported",
      "—",
      "—",
      "—",
      "Company investor Q&A confirms earlier PROTAC programs remain in early clinical development",
      "2025-04-25",
      "https://disc.static.szse.cn/disc/disk03/finalpage/2023-04-17/5654a016-14a7-434f-a5c8-ff7e3624f99f.PDF | https://pdf.dfcfw.com/pdf/H2_AN202504251662228192_1.PDF | https://disc.static.szse.cn/disc/disk03/finalpage/2026-08-27/8ef41362-8592-467c-8fba-38d4f313eb45.PDF | https://clinicaltrials.gov/study/NCT04861779",
      "2025-04-25"
    ],
    [
      "6",
      "HSK40118",
      "—",
      "Haisco Pharmaceutical Group Co., Ltd.",
      "China",
      "Mutant epidermal growth factor receptor (EGFR)",
      "EGFR-targeting PROTAC degrader",
      "Phase 1 — China (2023-03; registry last updated 2023-09)",
      "EGFR-mutant advanced non-small cell lung cancer",
      "NCT06050980",
      "None reported",
      "—",
      "—",
      "—",
      "Company investor Q&A confirms earlier PROTAC programs remain in early clinical development",
      "2025-04-25",
      "https://disc.static.szse.cn/disc/disk03/finalpage/2023-04-17/5654a016-14a7-434f-a5c8-ff7e3624f99f.PDF | https://pdf.dfcfw.com/pdf/H2_AN202504251662228192_1.PDF | https://disc.static.szse.cn/disc/disk03/finalpage/2026-08-27/8ef41362-8592-467c-8fba-38d4f313eb45.PDF | https://clinicaltrials.gov/study/NCT06050980",
      "2025-04-25"
    ],
    [
      "7",
      "ICP-538",
      "—",
      "InnoCare Pharma / Beijing InnoCare Pharma Tech Co., Ltd.",
      "China",
      "VAV1",
      "Oral CRBN-recruiting VAV1 molecular glue degrader",
      "Phase 1 — China (2026-03)",
      "Autoimmune disease development; healthy-volunteer first-in-human trial",
      "NCT07535099",
      "None reported",
      "—",
      "—",
      "—",
      "Phase 1 registry updated; recruiting",
      "2026-06-18",
      "https://www.innocarepharma.com/en/news/activity/en020260325-InnoCare-2025-Annual-Results | https://www.innocarepharma.com/en/contact | https://clinicaltrials.gov/study/NCT07535099",
      "2026-06-18"
    ]
  ],
  "row_sources": [
    [
      {
        "url": "https://www.prnewswire.com/news-releases/gt20029-china-phase-ii-trial-for-aga-reached-primary-endpoint-302122889.html",
        "source_date": "2025-08-12"
      },
      {
        "url": "https://en.kintor.com.cn/news/p-6-6.html",
        "source_date": "2025-08-12"
      },
      {
        "url": "https://www.kintor.com.cn/msg.html",
        "source_date": "2025-08-12"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06692465",
        "source_date": "2025-08-12"
      }
    ],
    [
      {
        "url": "https://www.hinovapharma.com/en/about.html",
        "source_date": "2026-08-27"
      },
      {
        "url": "https://static.cninfo.com.cn/finalpage/2026-08-27/1225514360.PDF",
        "source_date": "2026-08-27"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06155084",
        "source_date": "2026-08-27"
      }
    ],
    [
      {
        "url": "https://www.hengrui.com/images/investor/hk/2.%20Prospectus/2.%20Offer%20for%20Subscription%20%28EN%29.pdf",
        "source_date": "2026-10-22"
      },
      {
        "url": "https://static.cninfo.com.cn/finalpage/2026-03-26/1225032585.PDF",
        "source_date": "2026-10-22"
      },
      {
        "url": "https://static.cninfo.com.cn/finalpage/2026-08-20/1225483600.PDF",
        "source_date": "2026-10-22"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06555068",
        "source_date": "2026-10-22"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06679036",
        "source_date": "2026-10-22"
      }
    ],
    [
      {
        "url": "https://www.innocarepharma.com/en/news/activity/en020220706",
        "source_date": "2025-02-25"
      },
      {
        "url": "https://www.innocarepharma.com/en/contact",
        "source_date": "2025-02-25"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT05719701",
        "source_date": "2025-02-25"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06845241",
        "source_date": "2025-02-25"
      }
    ],
    [
      {
        "url": "https://disc.static.szse.cn/disc/disk03/finalpage/2023-04-17/5654a016-14a7-434f-a5c8-ff7e3624f99f.PDF",
        "source_date": "2025-04-25"
      },
      {
        "url": "https://pdf.dfcfw.com/pdf/H2_AN202504251662228192_1.PDF",
        "source_date": "2025-04-25"
      },
      {
        "url": "https://disc.static.szse.cn/disc/disk03/finalpage/2026-08-27/8ef41362-8592-467c-8fba-38d4f313eb45.PDF",
        "source_date": "2025-04-25"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT04861779",
        "source_date": "2025-04-25"
      }
    ],
    [
      {
        "url": "https://disc.static.szse.cn/disc/disk03/finalpage/2023-04-17/5654a016-14a7-434f-a5c8-ff7e3624f99f.PDF",
        "source_date": "2025-04-25"
      },
      {
        "url": "https://pdf.dfcfw.com/pdf/H2_AN202504251662228192_1.PDF",
        "source_date": "2025-04-25"
      },
      {
        "url": "https://disc.static.szse.cn/disc/disk03/finalpage/2026-08-27/8ef41362-8592-467c-8fba-38d4f313eb45.PDF",
        "source_date": "2025-04-25"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06050980",
        "source_date": "2025-04-25"
      }
    ],
    [
      {
        "url": "https://www.innocarepharma.com/en/news/activity/en020260325-InnoCare-2025-Annual-Results",
        "source_date": "2026-06-18"
      },
      {
        "url": "https://www.innocarepharma.com/en/contact",
        "source_date": "2026-06-18"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT07535099",
        "source_date": "2026-06-18"
      }
    ]
  ],
  "records": [
    {
      "rank": "1",
      "asset": "GT20029",
      "inn": "—",
      "originator": "Kintor Pharmaceutical Limited (Suzhou Kintor)",
      "country": "China",
      "target": "Androgen receptor (AR)",
      "mechanism": "Topical AR-targeting PROTAC degrader",
      "highest_stage": "Phase 2 — China (2023-04)",
      "indications": "Androgenetic alopecia; acne vulgaris",
      "trial_ids": "NCT06692465",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "China acne Phase 2 met its primary endpoint, company announcement",
      "latest_event_date": "2025-08-12",
      "source_urls": "https://www.prnewswire.com/news-releases/gt20029-china-phase-ii-trial-for-aga-reached-primary-endpoint-302122889.html | https://en.kintor.com.cn/news/p-6-6.html | https://www.kintor.com.cn/msg.html | https://clinicaltrials.gov/study/NCT06692465",
      "source_date": "2025-08-12"
    },
    {
      "rank": "2",
      "asset": "HP518",
      "inn": "—",
      "originator": "Hinova Pharmaceuticals Inc.",
      "country": "China",
      "target": "Androgen receptor (AR)",
      "mechanism": "Oral AR-targeting PROTAC degrader",
      "highest_stage": "Phase 2 — China (2024-12)",
      "indications": "Metastatic castration-resistant prostate cancer",
      "trial_ids": "NCT06155084",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Hinova interim disclosure describes China Phase 2 development and combination IND progress",
      "latest_event_date": "2026-08-27",
      "source_urls": "https://www.hinovapharma.com/en/about.html | https://static.cninfo.com.cn/finalpage/2026-08-27/1225514360.PDF | https://clinicaltrials.gov/study/NCT06155084",
      "source_date": "2026-08-27"
    },
    {
      "rank": "3",
      "asset": "HRS-1358",
      "inn": "—",
      "originator": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.",
      "country": "China",
      "target": "Estrogen receptor (ER)",
      "mechanism": "Oral ER-targeting PROTAC degrader",
      "highest_stage": "Phase 2 — China (confirmed 2025-05; combination)",
      "indications": "Advanced breast cancer, combination therapy",
      "trial_ids": "NCT06555068 | NCT06679036",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Combination-study registry updated; recruiting",
      "latest_event_date": "2026-10-22",
      "source_urls": "https://www.hengrui.com/images/investor/hk/2.%20Prospectus/2.%20Offer%20for%20Subscription%20%28EN%29.pdf | https://static.cninfo.com.cn/finalpage/2026-03-26/1225032585.PDF | https://static.cninfo.com.cn/finalpage/2026-08-20/1225483600.PDF | https://clinicaltrials.gov/study/NCT06555068 | https://clinicaltrials.gov/study/NCT06679036",
      "source_date": "2026-10-22"
    },
    {
      "rank": "4",
      "asset": "ICP-490",
      "inn": "—",
      "originator": "InnoCare Pharma / Beijing InnoCare Pharma Tech Co., Ltd.",
      "country": "China",
      "target": "IKZF1 (Ikaros); IKZF3 (Aiolos)",
      "mechanism": "CRBN-recruiting molecular glue degrader",
      "highest_stage": "Phase 1/2 — China (2023-03; registry status unknown)",
      "indications": "Relapsed/refractory multiple myeloma; non-Hodgkin lymphoma",
      "trial_ids": "NCT05719701 | NCT06845241",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "NHL Phase 1/2 registered; not yet recruiting",
      "latest_event_date": "2025-02-25",
      "source_urls": "https://www.innocarepharma.com/en/news/activity/en020220706 | https://www.innocarepharma.com/en/contact | https://clinicaltrials.gov/study/NCT05719701 | https://clinicaltrials.gov/study/NCT06845241",
      "source_date": "2025-02-25"
    },
    {
      "rank": "5",
      "asset": "HSK29116",
      "inn": "—",
      "originator": "Haisco Pharmaceutical Group Co., Ltd.",
      "country": "China",
      "target": "Bruton tyrosine kinase (BTK)",
      "mechanism": "BTK-targeting PROTAC degrader",
      "highest_stage": "Phase 1 — China / Australia (2021-08; registry status unknown)",
      "indications": "Relapsed/refractory B-cell malignancies",
      "trial_ids": "NCT04861779",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company investor Q&A confirms earlier PROTAC programs remain in early clinical development",
      "latest_event_date": "2025-04-25",
      "source_urls": "https://disc.static.szse.cn/disc/disk03/finalpage/2023-04-17/5654a016-14a7-434f-a5c8-ff7e3624f99f.PDF | https://pdf.dfcfw.com/pdf/H2_AN202504251662228192_1.PDF | https://disc.static.szse.cn/disc/disk03/finalpage/2026-08-27/8ef41362-8592-467c-8fba-38d4f313eb45.PDF | https://clinicaltrials.gov/study/NCT04861779",
      "source_date": "2025-04-25"
    },
    {
      "rank": "6",
      "asset": "HSK40118",
      "inn": "—",
      "originator": "Haisco Pharmaceutical Group Co., Ltd.",
      "country": "China",
      "target": "Mutant epidermal growth factor receptor (EGFR)",
      "mechanism": "EGFR-targeting PROTAC degrader",
      "highest_stage": "Phase 1 — China (2023-03; registry last updated 2023-09)",
      "indications": "EGFR-mutant advanced non-small cell lung cancer",
      "trial_ids": "NCT06050980",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company investor Q&A confirms earlier PROTAC programs remain in early clinical development",
      "latest_event_date": "2025-04-25",
      "source_urls": "https://disc.static.szse.cn/disc/disk03/finalpage/2023-04-17/5654a016-14a7-434f-a5c8-ff7e3624f99f.PDF | https://pdf.dfcfw.com/pdf/H2_AN202504251662228192_1.PDF | https://disc.static.szse.cn/disc/disk03/finalpage/2026-08-27/8ef41362-8592-467c-8fba-38d4f313eb45.PDF | https://clinicaltrials.gov/study/NCT06050980",
      "source_date": "2025-04-25"
    },
    {
      "rank": "7",
      "asset": "ICP-538",
      "inn": "—",
      "originator": "InnoCare Pharma / Beijing InnoCare Pharma Tech Co., Ltd.",
      "country": "China",
      "target": "VAV1",
      "mechanism": "Oral CRBN-recruiting VAV1 molecular glue degrader",
      "highest_stage": "Phase 1 — China (2026-03)",
      "indications": "Autoimmune disease development; healthy-volunteer first-in-human trial",
      "trial_ids": "NCT07535099",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Phase 1 registry updated; recruiting",
      "latest_event_date": "2026-06-18",
      "source_urls": "https://www.innocarepharma.com/en/news/activity/en020260325-InnoCare-2025-Annual-Results | https://www.innocarepharma.com/en/contact | https://clinicaltrials.gov/study/NCT07535099",
      "source_date": "2026-06-18"
    }
  ]
}